Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found that the Leptin receptor is a consistent marker for hair follicle dermal cells, which may help future hair research.

IL-10 may worsen alopecia areata instead of helping it.

T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.

Targeting Vδ1+T-cells may help treat alopecia areata.

Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.

Higher PD-1 levels mean fewer CD8+ T cells in alopecia areata hair follicles.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

IL-36α helps in growing new hair follicles when healing wounds, potentially aiding in hair growth.

IL-1 and IL-7 help activate cells that boost hair follicle stem cell growth, aiding wound healing.

Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.

Trichohyalin may trigger the immune response causing alopecia areata.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Platelet Rich Plasma reduces psoriasis symptoms but isn't enough alone for treatment.

Targeting IL-17 could help treat pattern hair loss.

PRDX5 enzyme may contribute to alopecia areata by affecting oxidative stress and autoimmunity.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Blocking CXCL12 can reverse hair loss and fibrosis in androgenetic alopecia.

hsa_circ_0002980 can help stop liver cancer cells from growing and spreading.

Autoimmune reactions may cause both alopecia areata and HAM.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

Basal cell carcinomas may use IDO to protect themselves from the immune system.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Activating Tgr5 may help treat hair loss and bone loss.

Higher IL-37 levels are linked to more severe alopecia areata, but the gene variation doesn't affect disease risk.

Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.

Targeting the AhR pathway may help treat alopecia areata.

The humanized AA mouse model is better for testing new alopecia areata treatments.